S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
This Could Be THE Watershed Moment of Our Financial Lives (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Former Deutsche Bank Co-CEO Anshu Jain dies
The Safest Option in Trades! (Ad)pixel
High oil prices help Saudi Aramco earn $88B in first half
Germans urged to cap heat in offices this winter to save gas
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
The Safest Option in Trades! (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
This Could Be THE Watershed Moment of Our Financial Lives (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Former Deutsche Bank Co-CEO Anshu Jain dies
The Safest Option in Trades! (Ad)pixel
High oil prices help Saudi Aramco earn $88B in first half
Germans urged to cap heat in offices this winter to save gas
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
The Safest Option in Trades! (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
This Could Be THE Watershed Moment of Our Financial Lives (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Former Deutsche Bank Co-CEO Anshu Jain dies
The Safest Option in Trades! (Ad)pixel
High oil prices help Saudi Aramco earn $88B in first half
Germans urged to cap heat in offices this winter to save gas
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
The Safest Option in Trades! (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
This Could Be THE Watershed Moment of Our Financial Lives (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Former Deutsche Bank Co-CEO Anshu Jain dies
The Safest Option in Trades! (Ad)pixel
High oil prices help Saudi Aramco earn $88B in first half
Germans urged to cap heat in offices this winter to save gas
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
The Safest Option in Trades! (Ad)pixel
NASDAQ:FIXX

Homology Medicines - FIXX Stock Forecast, Price & News

$2.76
-0.09 (-3.16%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.60
$2.93
50-Day Range
$1.78
$2.97
52-Week Range
$1.30
$8.90
Volume
129,905 shs
Average Volume
193,704 shs
Market Capitalization
$158.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.01

Homology Medicines MarketRank™ Forecast

Analyst Rating
Hold
2.43 Rating Score
Upside/​Downside
371.4% Upside
$13.01 Price Target
Short Interest
Healthy
2.89% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.33
Upright™ Environmental Score
News Sentiment
1.23mentions of Homology Medicines in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.86) to ($1.93) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.47 out of 5 stars

Medical Sector

218th out of 1,135 stocks

Pharmaceutical Preparations Industry

99th out of 557 stocks

FIXX stock logo

About Homology Medicines (NASDAQ:FIXX) Stock

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.

Homology Medicines Stock Performance

Shares of Homology Medicines stock opened at $2.76 on Friday. The stock has a market cap of $158.40 million, a P/E ratio of -34.50 and a beta of -0.36. The stock's fifty day moving average is $2.22 and its 200 day moving average is $2.49. Homology Medicines has a one year low of $1.30 and a one year high of $8.90.

Homology Medicines (NASDAQ:FIXX - Get Rating) last announced its quarterly earnings data on Monday, May 16th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.25) by $0.05. Homology Medicines had a negative return on equity of 49.48% and a negative net margin of 47.29%. The company had revenue of $0.80 million during the quarter, compared to the consensus estimate of $1.30 million. Analysts predict that Homology Medicines will post -1.86 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on FIXX. Chardan Capital decreased their price objective on shares of Homology Medicines to $14.00 and set a "na" rating for the company in a report on Tuesday, May 17th. HC Wainwright reiterated a "buy" rating and issued a $20.00 price objective on shares of Homology Medicines in a report on Monday, May 23rd. Finally, Credit Suisse Group set a $3.10 target price on shares of Homology Medicines in a research note on Monday, June 20th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $13.01.

Receive FIXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Homology Medicines and its competitors with MarketBeat's FREE daily newsletter.

FIXX Stock News Headlines

Homology Medicines Inc - Stock Quote FIXX
See More Headlines
Receive FIXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Homology Medicines and its competitors with MarketBeat's FREE daily newsletter.

FIXX Company Calendar

Last Earnings
5/16/2022
Today
8/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FIXX
Fax
N/A
Employees
224
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$13.01
High Stock Price Forecast
$29.00
Low Stock Price Forecast
$3.10
Forecasted Upside/Downside
+371.4%
Consensus Rating
Hold
Rating Score (0-4)
2.43
Research Coverage
7 Analysts

Profitability

Net Income
$-95,760,000.00
Pretax Margin
-18.80%

Debt

Sales & Book Value

Annual Sales
$33.97 million
Book Value
$2.97 per share

Miscellaneous

Free Float
44,474,000
Market Cap
$158.40 million
Optionable
Not Optionable
Beta
-0.36

Key Executives

  • Dr. Arthur O. Tzianabos Ph.D. (Age 59)
    CEO & Director
    Comp: $912.5k
  • Dr. Albert Seymour Ph.D. (Age 54)
    Pres & Chief Scientific Officer
    Comp: $638.7k
  • Mr. W. Bradford Smith CPA (Age 66)
    M.B.A., CFO, Treasurer & Chief Bus. Officer
    Comp: $755.8k
  • Dr. Saswati Chatterjee Ph.D.
    Co-Founder & Member of Scientific Advisory Board
  • Dr. Julie Jordan M.D.
    Sr. VP and Head of Clinical Devel. & Operations
  • Dr. Paul Alloway J.D. (Age 51)
    Ph.D., Chief Legal Officer & Sec.
  • Ms. Theresa McNeely (Age 58)
    Chief Communications Officer & Patient Advocate
  • Ms. Melissa Gelormini
    VP of HR
  • Mr. Michael Blum M.B.A. (Age 54)
    Chief Commercial Officer
  • Dr. Deborah Kinch Ph.D.
    Chief Devel. Officer













FIXX Stock - Frequently Asked Questions

Should I buy or sell Homology Medicines stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Homology Medicines in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" FIXX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FIXX, but not buy additional shares or sell existing shares.
View FIXX analyst ratings
or view top-rated stocks.

What is Homology Medicines' stock price forecast for 2022?

7 Wall Street analysts have issued twelve-month target prices for Homology Medicines' stock. Their FIXX share price forecasts range from $3.10 to $29.00. On average, they anticipate the company's share price to reach $13.01 in the next year. This suggests a possible upside of 371.4% from the stock's current price.
View analysts price targets for FIXX
or view top-rated stocks among Wall Street analysts.

How have FIXX shares performed in 2022?

Homology Medicines' stock was trading at $3.64 at the start of the year. Since then, FIXX shares have decreased by 24.2% and is now trading at $2.76.
View the best growth stocks for 2022 here
.

How were Homology Medicines' earnings last quarter?

Homology Medicines, Inc. (NASDAQ:FIXX) announced its quarterly earnings data on Monday, May, 16th. The company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.05. The firm had revenue of $0.80 million for the quarter, compared to analysts' expectations of $1.30 million. Homology Medicines had a negative net margin of 47.29% and a negative trailing twelve-month return on equity of 49.48%.

What other stocks do shareholders of Homology Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Homology Medicines investors own include Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Gossamer Bio (GOSS), Spero Therapeutics (SPRO), Alector (ALEC), Dynavax Technologies (DVAX), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO).

When did Homology Medicines IPO?

(FIXX) raised $100 million in an IPO on Wednesday, March 28th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Evercore ISI acted as the underwriters for the IPO and BTIG was co-manager.

What is Homology Medicines' stock symbol?

Homology Medicines trades on the NASDAQ under the ticker symbol "FIXX."

Who are Homology Medicines' major shareholders?

Homology Medicines' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include FMR LLC (1.25%), JPMorgan Chase & Co. (1.24%), Group One Trading L.P. (0.00%), Renaissance Technologies LLC (0.43%), Connor Clark & Lunn Investment Management Ltd. (0.40%) and UBS Group AG (0.33%). Insiders that own company stock include Albert Seymour, Arthur Tzianabos, James E Flynn, Kush Parmar, Timothy P Kelly, Timothy P Kelly and W Bradford Smith.
View institutional ownership trends
.

How do I buy shares of Homology Medicines?

Shares of FIXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Homology Medicines' stock price today?

One share of FIXX stock can currently be purchased for approximately $2.76.

How much money does Homology Medicines make?

Homology Medicines (NASDAQ:FIXX) has a market capitalization of $158.40 million and generates $33.97 million in revenue each year. The company earns $-95,760,000.00 in net income (profit) each year or ($0.08) on an earnings per share basis.

How many employees does Homology Medicines have?

The company employs 224 workers across the globe.

How can I contact Homology Medicines?

Homology Medicines' mailing address is ONE PATRIOTS PARK, BEDFORD MA, 01730. The official website for the company is www.homologymedicines.com. The company can be reached via phone at (781) 301-7277.

This page (NASDAQ:FIXX) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.